IOSR Journal of Biotechnology and Biochemistry (IOSR-JBB)
ISSN: 2455-264X, Volume 12, Issue 3 Series 1 (May. – June. 2026), PP 35-40
www.iosrjournals.org

Role Of Sialyltransferases In Tumor Progression And Cancer Metastasis: A Comprehensive Review Article

Ms. Riya
(Medical Laboratory Technology Department, A&M Institute Of Computer & Technology, Pathankot, India.)

Abstract
Cancer progression is closely associated with alterations in glycosylation, particularly hyper sialylation mediated by sialyltransferases (STs). Sialylation is a critical post-translational modification involving the transfer of sialic acid residues to glycoproteins and glycolipids, thereby regulating cellular communication, adhesion, immune recognition, and metastatic behavior. Aberrant expression of sialyltransferases has emerged as a hallmark of malignant transformation and contributes significantly to tumor growth, invasion, immune evasion, metastasis, and therapeutic resistance. Human sialyltransferases are categorized into four major families: ST3Gal, ST6Gal, ST6GalNAc, and ST8Sia, based on substrate specificity and glycosidic linkage formation. Increasing evidence indicates that overexpression of STs promotes synthesis of tumor-associated carbohydrate antigens such as sialyl Lewis X (sLeX) and sialyl Lewis A (sLeA), which facilitate metastatic dissemination through interactions with selectins and Siglecs. Furthermore, ST-mediated hyper sialylation creates a protective glycocalyx around tumor cells, reducing susceptibility to apoptosis and anticancer therapies. Recent advances in glycobiology and structural biology have enabled the development of sialyltransferase inhibitors as promising therapeutic agents against metastatic cancers. This review comprehensively discusses the molecular mechanisms of sialyltransferases, their classification, involvement in cancer progression, immune modulation, metastasis, and the emerging therapeutic opportunities targeting aberrant sialylation pathways.

Keywords: *Sialyltransferases, Cancer Metastasis, Glycosylation, Hyper sialylation, Tumor Progression, Glycobiology, Therapeutic Targets, Siglecs, Selectins*

Date of Submission: 13-05-2026 Date of Acceptance: 23-05-2026

I. Background

Cancer progression and metastasis are strongly influenced by alterations in cellular glycosylation patterns. Among these alterations, hypersialylation has emerged as one of the most significant hallmarks of malignant transformation. Sialyltransferases are a family of glycosyltransferase enzymes responsible for transferring sialic acid residues onto glycoproteins and glycolipids, thereby regulating cellular adhesion, immune recognition, migration, and signaling. Aberrant expression of sialyltransferases contributes to tumor growth, immune evasion, metastasis, and resistance to chemotherapy. Human sialyltransferases are classified into four major groups: ST3Gal, ST6Gal, ST6GalNAc, and ST8Sia, each involved in the synthesis of distinct sialylated glycoconjugates. Recent studies have demonstrated that overexpression of these enzymes is associated with aggressive cancer phenotypes and poor prognosis in multiple cancers, including ovarian, breast, colorectal, and glioma cancers. This review summarizes the role of sialyltransferases in cancer biology, mechanisms of aberrant sialylation, involvement in metastasis and immune modulation, and current advances in sialyltransferase-targeted therapeutics. Understanding the molecular mechanisms of sialyltransferase-mediated tumor progression may provide novel opportunities for biomarker development and targeted cancer therapy.

II. Introduction

Cancer is one of the leading causes of mortality worldwide and is characterized by uncontrolled cell proliferation, invasion, and metastasis. Tumors arise when normal cellular regulatory mechanisms become disrupted due to genetic and epigenetic alterations. Tumors are generally classified into three categories: benign tumors, malignant tumors, and precancerous lesions. Among these, malignant tumors possess the ability to invade surrounding tissues and metastasize to distant organs, making them highly life-threatening.

Tumor development occurs through a multistep process involving initiation, promotion or progression, and metastasis. During initiation, carcinogenic agents induce mutations in cellular DNA, resulting in dysregulated signaling pathways. Promotion and progression involve rapid proliferation and acquisition of invasive characteristics. Finally, metastasis allows cancer cells to spread through blood circulation or lymphatic systems to distant organs.

Recent advances in glycobiology have identified glycosylation abnormalities as critical contributors to cancer progression. Glycosylation is a post-translational modification in which carbohydrate moieties are attached to proteins and lipids. One important form of glycosylation is sialylation, involving the addition of sialic acid residues to glycoproteins and glycolipids. Increased sialylation, commonly referred to as hypersialylation, is frequently observed in cancer cells and is strongly associated with metastasis, immune evasion, and therapeutic resistance.

Sialyltransferases (STs) are the enzymes responsible for catalyzing sialylation reactions. Altered expression of these enzymes has been implicated in several types of cancer and is considered a hallmark of malignant transformation. This review discusses the biological significance of sialyltransferases in cancer progression and highlights their therapeutic potential.

III. Glycosylation And Sialylation In Cancer

Glycosylation is an essential post-translational modification occurring mainly in the endoplasmic reticulum and Golgi apparatus. It involves the attachment of glycans to proteins and lipids through glycosidic bonds. Glycosylation regulates numerous biological functions including protein folding, stability, cell-cell communication, and immune recognition.

In cancer cells, glycosylation patterns become significantly altered. One of the most common changes is hypersialylation, characterized by increased density of sialic acid-containing glycans on the cell surface. Sialic acids are negatively charged monosaccharides typically located at the terminal positions of glycoconjugates.

Sialylation contributes to tumor progression through several mechanisms:

- Enhancement of cancer cell migration and invasion
- Reduction of immune cell recognition
- Promotion of metastatic spread
- Increased resistance to apoptosis
- Alteration of cell adhesion and signaling pathways

The most common forms of sialic acid in humans are N-acetylneuraminic acid (Neu5Ac) and N-glycolylneuraminic acid (Neu5Gc). Neu5Gc is obtained primarily from dietary sources such as red meat and has been linked to inflammation and tumor progression.

Aberrant sialylation influences tumor cell interactions with selectins and siglecs, thereby facilitating metastasis and immune suppression. Increased sialylation also forms a protective glycocalyx around cancer cells, reducing the effectiveness of chemotherapeutic agents.

IV. Sialyltransferases And Their Classification

Sialyltransferases are glycosyltransferase enzymes that catalyze the transfer of sialic acid residues from the donor substrate cytidine monophosphate-N-acetylneuraminic acid (CMP-Neu5Ac) to glycoproteins and glycolipids.

Humans possess approximately 20 identified sialyltransferases, which are classified into four major families according to substrate specificity and glycosidic linkage formation.

ST3Gal Family

The ST3Gal family includes ST3Gal I to ST3Gal VI. These enzymes catalyze the formation of α2,3-linkages between sialic acid and terminal galactose residues present on glycoproteins and glycolipids.

Overexpression of ST3Gal enzymes is associated with increased synthesis of sialyl Lewis antigens (sLeX and sLeA), which function as selectin ligands and promote metastatic dissemination.

ST6Gal Family

The ST6Gal family consists of ST6Gal I and ST6Gal II. These enzymes transfer sialic acid residues through α2,6-linkages to N-acetyl lactosamine structures.

ST6Gal I has been strongly associated with enhanced tumor survival, cell migration, resistance to apoptosis, and chemotherapy resistance in multiple cancers.

ST6GalNAc Family

The ST6GalNAc family includes six enzymes (ST6GalNAc I-VI) responsible for adding sialic acid residues to N-acetylgalactosamine-containing substrates.

These enzymes are involved in the synthesis of tumor-associated carbohydrate antigens and contribute to immune evasion and cancer progression.

ST8Sia Family

The ST8Sia family consists of ST8Sia I-VI and is responsible for α2,8-linked sialic acid formation. Certain members, including ST8Sia II and ST8Sia IV, are polysialyltransferases involved in polysialic acid synthesis.

Polysialylation reduces cell adhesion and enhances cellular motility, thereby facilitating metastasis.



Reference from Sialyltransferases and Neuraminidases: Potential Targets for Cancer Treatment.

V. Role Of Sialyltransferases In Tumor Progression

Aberrant expression of sialyltransferases is a common feature of cancer cells. Increased activity of these enzymes leads to altered glycosylation patterns that support malignant behavior.

Tumor Growth and Survival

Sialyltransferases promote tumor growth by enhancing signaling pathways involved in proliferation and survival. Increased sialylation protects tumor cells from apoptosis and enables adaptation to hostile microenvironments.

Metastasis

Metastasis is the primary cause of cancer-related mortality. Sialyltransferases contribute to metastasis by increasing the expression of selectin ligands such as sLeX and sLeA. These ligands mediate adhesion between circulating tumor cells and endothelial cells, facilitating extravasation into distant tissues.

Immune Evasion

Cancer-associated sialoglycans interact with sialic acid-binding immunoglobulin-type lectins (Siglecs) expressed on immune cells. This interaction suppresses immune responses and allows tumor cells to evade immune surveillance.

Chemotherapy and Radiotherapy Resistance

Hypersialylation forms a physical and biochemical barrier around tumor cells, reducing drug penetration and enhancing resistance to chemotherapy and radiotherapy.

VI. Sialic Acid-Binding Proteins In Cancer

Siglecs

Siglecs are sialic acid-binding immunoglobulin-like lectins predominantly expressed on immune cells. Tumor-associated sialoglycans bind to Siglecs and suppress immune activation.

Different Siglec family members regulate immune tolerance and inflammation within the tumor microenvironment. Increased interaction between Siglecs and tumor glycans contributes to immune escape.

Selectins

Selectins are calcium-dependent lectins involved in leukocyte trafficking and inflammation. The three major selectins include:

- E-selectin
- L-selectin
- P-selectin

Tumor cells expressing sialyl Lewis antigens bind to selectins on endothelial cells and platelets, promoting adhesion and metastatic spread.

Overexpression of selectin ligands is often associated with poor prognosis in several cancers.

VII. Biosynthesis And Regulation Of Sialic Acid

Sialic acid biosynthesis begins in the cytosol from fructose-6-phosphate and proceeds through multiple enzymatic steps to generate CMP-Neu5Ac. The activated donor molecule is then transported to the Golgi apparatus where sialyltransferases catalyze glycan sialylation.

Degradation of sialylated glycoconjugates is mediated by sialidases or neuraminidases. Humans possess four major sialidases:

- NEU1 (lysosomal)
- NEU2 (cytosolic)
- NEU3 (plasma membrane-associated)
- NEU4 (lysosomal/mitochondrial)

Dysregulation of these enzymes contributes to altered sialylation patterns in cancer.

VIII. Therapeutic Potential Of Sialyltransferase Inhibitors

Due to their major role in cancer progression, sialyltransferases are considered promising therapeutic targets. Several categories of sialyltransferase inhibitors have been developed:

1. Sialic acid analogs
2. CMP-sialic acid analogs
3. Cytidine analogs
4. Oligosaccharide derivatives
5. Aromatic compounds
6. Flavonoids
7. Lithocholic acid analogs
8. Dual-substrate analogs

Experimental studies have demonstrated that inhibition of sialyltransferase activity reduces tumor growth and metastasis in animal models including glioma and ovarian cancer.

Computational approaches such as homology modeling, molecular docking, and structure-based drug design are currently being employed to identify novel inhibitors.

IX. Materials And Methods

The present review article was prepared using published scientific literature related to sialyltransferases, glycosylation, and cancer biology.

The following methodologies and tools commonly used in sialyltransferase research are discussed:

Homology Modeling

Homology modeling is a computational approach used to predict protein structures based on sequence similarity with known proteins. It assists in understanding enzyme structure and designing inhibitors.

Molecular Docking (AutoDock)

AutoDock is widely used for predicting interactions between small molecules and protein targets. It helps identify potential sialyltransferase inhibitors.

PyMOL Visualization

PyMOL is a molecular visualization software used for 3D structural analysis of proteins and ligand interactions.

X. Discussion

The present review highlights the crucial role of sialyltransferases in regulating cancer progression, metastasis, and immune modulation. Altered glycosylation, particularly hypersialylation, is now recognized as a major hallmark of cancer biology. Tumor cells exploit aberrant sialylation to enhance survival, increase motility, evade immune surveillance, and establish metastatic lesions in distant organs.

One of the most significant observations in cancer glycobiology is the overexpression of ST3Gal and ST6Gal family enzymes in aggressive tumors. Increased activity of ST3Gal III, ST3Gal IV, and ST6Gal I results in elevated synthesis of selectin ligands such as sLeX and sLeA. These carbohydrate antigens facilitate interactions between circulating tumor cells and endothelial cells, thereby promoting metastatic dissemination. Clinical studies have associated overexpression of these glycans with poor prognosis in pancreatic, gastric, colorectal, ovarian, breast, and lung cancers.

Sialyltransferases also play a major role in tumor immune escape. Tumor-associated sialoglycans interact with immune inhibitory receptors called Siglecs that are expressed on leukocytes. Binding of cancer-associated glycans to Siglecs suppresses immune activation and promotes immune tolerance. This mechanism enables tumor cells to avoid phagocytosis and cytotoxic destruction by immune cells.

Another important aspect is the relationship between hypersialylation and chemotherapy resistance. Increased surface sialylation forms a dense glycocalyx barrier around tumor cells, limiting drug penetration and protecting cells from apoptosis. Studies involving ST6Gal I have demonstrated increased resistance to chemotherapeutic agents such as cisplatin and paclitaxel.

The biosynthesis and regulation of sialic acid metabolism further demonstrate the complexity of cancer-associated glycosylation. Human cells tightly regulate CMP-Neu5Ac synthesis and transport within the Golgi apparatus. However, cancer cells often exhibit increased metabolic flux through the sialic acid biosynthetic pathway, resulting in enhanced substrate availability and abnormal glycan production.

Structural and mechanistic studies have provided further insights into sialyltransferase function. Conserved motifs such as sialylmotifs L, S, and VS are essential for substrate recognition and catalytic activity. Crystal structural analysis of human α2,6-sialyltransferase has also improved understanding of enzyme-substrate interactions and has accelerated the design of selective inhibitors.

Sialyltransferase inhibitors have gained considerable attention as potential anticancer therapeutics. Different classes of inhibitors, including sialic acid analogs, CMP-sialic acid analogs, flavonoids, cytidine derivatives, and dual-substrate analogs, have shown promising results in experimental models. Inhibition of ST activity has been associated with reduced tumor growth, decreased metastatic potential, and improved immune responses in several cancer models including ovarian cancer and glioma.

In addition to therapeutic targeting, altered sialylation patterns may serve as important diagnostic and prognostic biomarkers. Elevated serum sialic acid levels and increased expression of specific sialylated antigens have been observed in multiple malignancies and may support early cancer detection and disease monitoring.

Despite major advances, several limitations remain in this field. Structural similarities among different ST families complicate the development of highly selective inhibitors. Furthermore, glycosylation pathways are highly dynamic and interconnected, making therapeutic targeting challenging. Future research should focus on selective glycoengineering strategies, combination immunotherapies, and translational clinical studies.

Overall, the study of sialyltransferases has significantly expanded our understanding of cancer glycobiology. Continued research in this area may lead to novel biomarkers and highly effective targeted therapies against metastatic cancers.

XI. Conclusion

Hypersialylation is a major hallmark of cancer progression and metastasis. Sialyltransferases play critical roles in regulating tumor growth, immune evasion, metastatic dissemination, and resistance to therapy.

The abnormal expression of sialyltransferases in cancer cells has made them promising biomarkers and therapeutic targets. Inhibition of these enzymes has shown encouraging results in preclinical studies and may lead to novel treatment strategies for metastatic cancers.

Further investigations into the molecular mechanisms of sialylation and development of selective inhibitors may contribute significantly to future cancer therapeutics.

References

[1]. Pietrobono S, Stecca B. Aberrant Sialylation In Cancer: Biomarker And Potential Target For Therapeutic Intervention? Cancers (Basel). 2021;13(9):2014. Doi:10.3390/Cancers13092014.
[2]. Perez SJLP, Fu CW, Li WS. Sialyltransferase Inhibitors For The Treatment Of Cancer Metastasis: Current Challenges And Future Perspectives. Molecules. 2021;26(18):5673. Doi:10.3390/Molecules26185673.
[3]. Bhide GP, Colley KJ. Sialylation Of N-Glycans: Mechanism, Cellular Compartmentalization And Function. Histochem Cell Biol. 2017;147(2):149–174. Doi:10.1007/S00418-016-1520-X.
[4]. Szabo R. New Avenues In The Design Of Sialyltransferase Inhibitors. 2017.
[5]. Chen JH. Tumour Invasion And Metastasis. Tzu Chi Med J. 2002;14(1):1–5. Doi:10.1016/S0959-8049(01)80498-6.
[6]. Tuccillo FM, Et Al. Aberrant Glycosylation As Biomarker For Cancer: Focus On CD43. Biomed Res Int. 2014;2014:742831. Doi:10.1155/2014/742831.
[7]. Lu J, Gu J. Significance Of B-Galactoside A2,6 Sialyltransferase 1 In Cancers. Molecules. 2015;20(5):7509–7527. Doi:10.3390/Molecules20057509.
[8]. Huang J, Huang J, Zhang G. Insights Into The Role Of Sialylation In Cancer Metastasis, Immunity, And Therapeutic Opportunity. Cancers (Basel). 2022;14(23):5840. Doi:10.3390/Cancers14235840.

[9]. Pearce OMT, Läubli H. Sialic Acids In Cancer Biology And Immunity. Glycobiology. 2015;26(2):111–128. Doi:10.1093/Glycob/Cwv097.
[10]. Wang L, Wang L, Liua Y, Wu L, Sun X. Sialyltransferase Inhibition And Recent Advances. 2016.
[11]. Büll C, Stoel MA, Den Brok MH, Adema GJ. Sialic Acids Sweeten A Tumor's Life. Cancer Res. 2014;74(12):3199–3204. Doi:10.1158/0008-5472.CAN-14-0728.
[12]. Bowles WHD, Gloster TM. Sialidase And Sialyltransferase Inhibitors: Targeting Pathogenicity And Disease. Front Mol Biosci. 2021;8:705133. Doi:10.3389/Fmolb.2021.705133.
[13]. Skropeta D, Dobie C, Montgomery AP, Steele H, Szabo R, Yu H. Sialyltransferase Inhibitors As Potential Anti-Cancer Agents. Aust J Chem. 2021;74(11):758–766. Doi:10.1071/CH21195.
[14]. Coughlan CM, Breen KC. The Control Of Sialyltransferase Activity In Tumour-Cell Lines Derived From Different Tissues Is Multifactorial. FEBS Lett. 1995;369(2–3):260–262. Doi:10.1016/0014-5793(95)00761-W.
[15]. Selke P, Et Al. Glycation Interferes With The Expression Of Sialyltransferases In Meningiomas. Cells. 2021;10(12):3298. Doi:10.3390/Cells10123298.
[16]. Harduin-Lepers A, Vallejo-Ruiz V, Krzewinski-Recchi MA, Samyn-Petit B, Julien S, Delannoy P. The Human Sialyltransferase Family. Biochimie. 2001;83(8):727–737. Doi:10.1016/S0300-9084(01)01301-3.
[17]. Szabo R, Skropeta D. Advancement Of Sialyltransferase Inhibitors: Therapeutic Challenges And Opportunities. Med Res Rev. 2017;37(2):219–270. Doi:10.1002/Med.21407.
[18]. Audry M, Jeanneau C, Imberty A, Harduin-Lepers A, Delannoy P, Breton C. Current Trends In The Structure-Activity Relationships Of Sialyltransferases. Glycobiology. 2011;21(6):716–726. Doi:10.1093/Glycob/Cwq189.
[19]. Hugonnet M, Singh P, Haas Q, Von Gunten S. The Distinct Roles Of Sialyltransferases In Cancer Biology And Onco-Immunology. Front Immunol. 2021;12:799861. Doi:10.3389/Fimmu.2021.799861.
[20]. Lee WL, Wang PH. Aberrant Sialylation In Ovarian Cancers. J Chin Med Assoc. 2020;83(4):337–344. Doi:10.1097/JCMA.0000000000000252.
[21]. Buffone A, Weaver VM. Don't Sugar-Coat It: How Glycocalyx Composition Influences Cancer Progression. J Cell Biol. 2020;219(1):E201910070. Doi:10.1083/Jcb.201910070.
[22]. Li Y, Chen X. Sialic Acid Metabolism And Sialyltransferase: Natural Functions And Applications. Appl Microbiol Biotechnol. 2012;94(4):887–905. Doi:10.1007/S00253-012-4040-1.
[23]. Kuhn B, Benz J, Greif M, Engel A, Sobek H, Rudolph M. Crystal Structure Of Human A-2,6 Sialyltransferase. Acta Crystallogr Sect A Found Adv. 2014;70:C307. Doi:10.1107/S2053273314096922.
[24]. Treatment C. Sialyltransferases And Neuraminidases: Potential Targets For Cancer Treatment. 2022.
[25]. Gynecological Cell Line PDF.
[26]. Summary-12424752.